Overview

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company